IG
NBIX icon

ING Group’s Neurocrine Biosciences NBIX Stock Holding History

ING Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Buy
+102,200
New +$15.2M 0.08% 181
2024
Q1 		– Sell
-11,300
Closed -$1.49M – 596
2023
Q4 		$1.49M Buy
+11,300
New +$1.3M 0.01% 442

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ING Group's NBIX Position: Q2 2026 in Review

ING Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 102,200 shares worth $17.2M. The stake represents 0.08% of the portfolio and ranks #181 among its holdings. This is a return to the name: ING Group previously reported a position in NBIX as recently as Q4 2023.

ING Group first reported a position in NBIX in Q4 2023 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • ING Group held 102,200 shares of Neurocrine Biosciences worth $17.2M as of Q2 2026.
  • Neurocrine Biosciences was a new ING Group position in Q2 2026.
  • Neurocrine Biosciences made up 0.08% of ING Group's portfolio in Q2 2026, its #181 holding.
  • ING Group first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 2 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.